Short Interest in Theratechnologies Inc. (NASDAQ:THTX) Increases By 2,740.1%

Theratechnologies Inc. (NASDAQ:THTX) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 1,190,000 shares, an increase of 2,740.1% from the March 15th total of 41,900 shares. Approximately 6.2% of the company’s stock are sold short. Based on an average trading volume of 1,030,000 shares, the days-to-cover ratio is presently 1.2 days.

Theratechnologies Stock Performance

Shares of Theratechnologies stock opened at $2.57 on Tuesday. Theratechnologies has a 1 year low of $1.08 and a 1 year high of $3.13. The firm’s 50-day simple moving average is $1.63 and its 200-day simple moving average is $1.52. The firm has a market cap of $118.17 million, a PE ratio of -25.70 and a beta of 1.11.

Analyst Ratings Changes

Separately, Research Capitl upgraded shares of Theratechnologies to a “strong-buy” rating in a report on Friday, February 14th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. National Bank of Canada FI raised its position in shares of Theratechnologies by 29.4% during the 3rd quarter. National Bank of Canada FI now owns 186,815 shares of the company’s stock valued at $232,000 after acquiring an additional 42,435 shares in the last quarter. Wealthspire Advisors LLC raised its holdings in shares of Theratechnologies by 39.0% during the fourth quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company’s stock worth $129,000 after purchasing an additional 20,000 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Theratechnologies during the fourth quarter worth $27,000. Harbour Investments Inc. lifted its position in shares of Theratechnologies by 20.0% in the 4th quarter. Harbour Investments Inc. now owns 87,772 shares of the company’s stock worth $159,000 after buying an additional 14,655 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Theratechnologies in the 4th quarter valued at about $40,000.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.